Latest Conference Articles

May 16th 2025, 12:00pm

ASCO Annual Meeting

Breast cancer experts rank key abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.

May 15th 2025, 9:09pm

Neoadjuvant data from the ADAPTcycle trial confirmed the limited benefit of chemotherapy over endocrine therapy in high-risk HR-positive breast cancer.

May 15th 2025, 9:00pm

ESMO Breast Cancer Congress

Emiltatug Ledadotin generated initial responses and was tolerable in heavily pretreated patients with advanced/metastatic TNBC.

May 15th 2025, 8:09pm

ESMO Breast Cancer Congress

Puxitatug samrotecan demonstrated manageable safety and early efficacy in HR-positive/HER2-negative advanced breast cancer.

May 15th 2025, 6:14pm

ESMO Breast Cancer Congress

Adjuvant pertuzumab with trastuzumab and chemotherapy extended OS vs placebo with trastuzumab and chemotherapy in HER2-positive early breast cancer.

May 15th 2025, 4:39pm

ESMO Breast Cancer Congress

Treatment with T-DXd improved outcomes vs chemotherapy in pretreated patients with HR-positive, HER2-low/-ultralow metastatic breast cancer.

May 15th 2025, 12:05pm

Unpacking Key Data from ASH 2024

Panelists discuss how the 5-year follow-up data from the ZUMA-2 trial reveal sustained clinical benefit and durable responses for patients with relapsed/refractory mantle cell lymphoma (R/R MCL) treated with brexucabtagene autoleucel, potentially reshaping treatment paradigms by demonstrating long-term efficacy of CAR T-cell therapy in a historically challenging hematologic malignancy.

May 15th 2025, 12:00pm

Unpacking Key Data from ASH 2024

Panelists discuss how the combination of lisocabtagene maraleucel (liso-cel) and ibrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), as presented in the phase 1/2 TRANSCEND CLL 004 study, may redefine treatment strategies by highlighting the potential benefits of combining chimeric antigen receptor (CAR) T-cell therapy with targeted agents and reshaping perspectives on sequential vs combination approaches in high-risk CLL.

May 15th 2025, 12:00pm

Ahead of the 2025 ASCO Annual Meeting, lung cancer experts highlight the abstracts and related trials they’re looking forward to seeing at the meeting.

May 14th 2025, 11:36pm

ESMO Breast Cancer Congress

Subgroup analyses from EMBER-3 continued to demonstrated benefits with imlunestrant plus abemaciclib in ER-positive advanced breast cancer.

May 14th 2025, 12:00pm

ASCO Annual Meeting

To prepare for the 2025 ASCO Annual Meeting, breast cancer experts share the abstracts and discussions they’re most excited to see at the meeting.

May 9th 2025, 8:38pm

ASCO Annual Meeting

Poll results highlighted key lung cancer abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.

May 8th 2025, 12:05pm

Unpacking Key Data from ASH 2024

Panelists discuss how insights from the Liso-cel combined with ibrutinib (ibr) for relapsed/refractory chronic lymphocytic leukemia (R/R CLL) and small lymphocytic lymphoma (SLL) are highlighted through the primary results of the open-label, phase 1/2 Transcend CLL 004 study.

May 8th 2025, 12:00pm

Unpacking Key Data from ASH 2024

Panelists discuss how the updated results from Arm 8 of the Epcore NHL-2 trial on Fixed-Duration Epcoritamab + R-Mini-CHOP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL) ineligible for full-dose R-CHOP may influence treatment selection by offering a potentially effective alternative for this patient population

May 7th 2025, 12:00pm

American Urological Association Annual Meeting

Ultra-low PSA responses were linked with prolonged rPFS and delayed times to mCRPC and PSA progression for patients with mHSPC treated with darolutamide.

May 6th 2025, 12:00pm

AACR Annual Meeting

Phase 1 data support further exploration of botensilimab plus balstilimab in patients with hepatocellular carcinoma.

May 1st 2025, 12:05pm

Unpacking Key Data from ASH 2024

Panelists discuss how iopofosine I 131 demonstrated efficacy and safety in previously treated patients with Waldenstrom macroglobulinemia (WM) in the CLOVER-WaM study, potentially influencing the broader treatment paradigm by introducing a novel targeted radiopharmaceutical approach and shaping future research toward optimizing combination therapies and long-term outcomes.

May 1st 2025, 12:00pm

American Urological Association Annual Meeting

Experts revisit the most intriguing abstracts and data they saw presented at the 2025 American Urological Association Annual Meeting.

May 1st 2025, 12:00pm

Unpacking Key Data from ASH 2024

Panelists discuss how the 5-year follow-up data from the ZUMA-5 trial demonstrate sustained efficacy and durable remission of axicabtagene ciloleucel in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL), potentially signaling a paradigm shift toward considering chimeric antigen receptor (CAR) T-cell therapy as a more prominent early-line treatment option for these challenging lymphoma subtypes.

April 30th 2025, 8:36pm

AACR Annual Meeting

Adjuvant aumolertinib improved disease-free survival in complete resected stage II to IIIB non–small cell lung cancer harboring EGFR mutations.